2 years ago, the damage caused by the epidemic Covid-19 affecting people all over the world including the economic sector Covid-19 It is a test of public health systems around the world. This is still a challenge that we must keep an eye on.
On April 27, 65, Assoc. Prof. Dr. Pratap Singhasiwanon, secretary-general of SEmeotropmed network and former Dean of the Faculty of Tropical Medicine Mahidol University said at a press conference “Effectiveness of the COVID-19 Vaccine” organized by AstraZeneca Thailand Co. By stating that the important thing is to build immunity. to provide basic medical services to save lives and is an investment in health “vaccine” is therefore an important pillar of the security of public health in the world and the fight against the COVID-19 outbreak and new epidemics in the future
Reduce serious illnesses and deaths, important variables indicating vaccine effectiveness
“What is clear is that vaccination is a protection especially for serious side effects such as severe symptoms and death. We originally used the method for measuring antibody formation above well. But the effectiveness of vaccines in the real world This is reflected in real-world experience. Currently, key variables can be measured. especially to prevent patients from receiving treatment in the hospital and dying.” Assoc. Prof. Dr. Pratap said.
Viral vector – mRNA reduces hospitalization 91.3-92.5%
A new expert analysis of data from more than 79 case studies reveals that vaccines against COVID-19 that is widely used all over the world They are equally effective in preventing hospitalizations and deaths from COVID-19. After two doses of vaccination
The report clearly shows that both the COVID-19 vaccine of AstraZeneca The viral vector vaccine and the mRNA vaccine against COVID-19 are effective in preventing hospital admissions. is between 91.3-92.5% and mortality is between 91.4 – 93.3% in the same level without a statistically significant difference which covers patients of all ages
Although the data at the time of this analysis report were related to the delta species and its predecessors. But data from the new wave of outbreaks has indicated a similar effect on the effectiveness of vaccines in preventing severe symptoms from COVID-19 strains.Omikron
Professor Guy Thwaites, Director of the Clinical Research Unit at the University of Oxford in Vietnam, said: Covid-19 vaccine It is vital to save lives and help Southeast Asian countries return to normal in the past year.
Our expert analysis of data shows that the COVID-19 vaccine of AstraZeneca and the type of vaccine mRNA Currently used are effective in preventing COVID-19. at a high level And it is important information for governments and policy makers in the region. to consider the introduction of a vaccine against COVID-19 to apply to the people most appropriately during the next 12 months
Vaccine efficacy need to see long term results
Dr. Sunet Chuenkitmongkol, deputy director of the National Institute of Vaccines, said studies on vaccine effectiveness in Thailand have shown that antibodies are higher early after vaccination and protect us from various adverse reactions. We originally used antibody numbers as the main criterion and found that mRNA was very high compared to virus vectors and dead germs, including booster dose with mRNA and viral vectors is much higher than the lethal pathogen
However, several factors should be considered in combination. Not just the initial antibody response level. But the efficacy of vaccines must also be looked at from real case studies. To prove that the vaccine used is effective. It can effectively prevent hospitalizations and deaths from COVID-19.
“Over 79 studies looking at real vaccine use and found that the most widely used viral vector and mRNA vaccines are the most effective vaccines,” he said. They were all equally effective in preventing serious illnesses at a high level.”
The data analyzed by infectious disease experts from across Asia comes from the VIEW-hub, an interactive platform that provides world-class, visualized information on vaccine use and impact. It was developed in collaboration with the Johns Hopkins Bloomberg School of Public Health and the Center for Vaccination Access International. (International Vaccine Access Center)
from data from Thailand that is information from actual practice reflect that viral vector Provides protection against hospital admissions and death by eliminating the severity of infection equivalent to mRNA. People are well protected. especially the severity of the coronavirus and be protected from commonly used vaccines
“Therefore, vaccine assessments should not be variable in short-term efficacy. But have to look at the long term by breaking into hospital treatment and dying from Covid Dr. Sunet said.
Omikron with booster injection
Dr. Bruce Mungall, Regional Medical Director of Asia Vaccines and infectious diseases AstraZeneca said in the title “AstraZeneca Vaccine: Omikron and Third Booster Data”, stating that the emerging Omikron is a new strain. infecting people all over the world despite getting vaccinated Many people think that vaccines don’t work or not? Therefore, it is important to understand how effective vaccines are.
Data from the UK, where viral vectors and mRNA are now available in vaccines for protection against minor infections and illnesses, have been shown to reduce hospital admissions and severe illness. Well from Omicron, including Delta as well.
Viral vector – Can two doses of mRNA protect against omikron?
While the efficacy effect of reducing hospital admissions and deaths is interesting, data in the UK between Delta and Omikron people who received 2 doses of AstraZeneca or 2 doses of Pfizer. Obviously the numbers are almost the same. Meanwhile, both species, even if given 2 doses, will not protect against omikron well in the long run.
Dose booster is important to protect Omikron.
However, in preventing illness, hospitalization, long-term efficacy is considered to be good for both Delta and Omikron, but efficacy decreases by approximately 30% after 6 months, so booster doses are important.
Compared to 2 doses of vaccine and after giving “Booster Dose” According to UK data, hospital admissions prevention rates jumped more than 90% after a third dose in both Delta and Omikron.
“The efficacy of these three doses of vaccines should be in the same direction for both vaccines. Previously, it must be admitted that The ability to support omikron species may be less compared to other species. But with both vaccines, people can be confident that they can prevent severe symptoms and death from COVID-19.” Dr Bruce Mungall said.
